# Clinical and Translational Implications

## Vaccine Development Challenges
Parasite genotype-specific resistance complicates vaccine development by introducing heterogeneity in antigenic targets and efficacy across parasite populations.[^1^] Band et al. (2022) demonstrate that adaptive parasite loci can erode host-protective effects, implying similar risks for vaccine-mediated immunity if parasite lineages evade protective responses.[^2^]

## Genomic Therapy and Precision Medicine
Advances in genomic therapy for hemoglobinopathies raise questions about how altering host genotypes may shift selective pressures on parasites and reshape malaria epidemiology.[^3^] Integrating host and parasite genomics in clinical research can guide precision strategies that consider both therapeutic benefits and ecological consequences.

## Policy and Global Health Considerations
The WHO Malaria Vaccine Technology Roadmap emphasizes the need for durable, high-efficacy vaccines and ongoing surveillance to detect escape variants.[^1^] Findings from parasite GWAS should therefore inform vaccine design, post-licensure monitoring, and the prioritization of multi-antigen approaches resilient to parasite evolution.[^1^]

[^1^]: World Health Organization. *Malaria Vaccine Technology Roadmap* (2013). See `references.bib`.
[^2^]: Band, G., Leffler, E. M., Jallow, M., et al. *Nature* (2022). See `references.bib`.
[^3^]: The Awesome Power of Human Genetics of Infectious Disease. *Annual Reviews* (2022). See `references.bib`.
